What Panacur-C Treats: Main Uses and Benefits

Panacur-C is relevant for use in managing infections caused by specific gastrointestinal parasites. The medication may assist with addressing infections involving roundworms, hookworms, whipworms, and the Taenia genus of tapeworms. This application is generally used in contexts marked by increased discomfort or when active worm burden requires targeted attention, such as with newly acquired animals or during routine periodic deworming.

Therapeutic benefit may be gained through the management of symptom clusters that may become intense or disruptive due to parasitic activity. The treatment helps address symptom clusters related to parasitic activity that may interfere with daily comfort, such as chronic or acute diarrhea, vomiting, and noticeable physiological strain linked to internal irritation. It is considered relevant in conditions presenting with nutritional impairment, such as symptoms related to unexplained weight loss and lethargy.

Through its action on the parasites, the treatment provides support that helps ease the overall symptom burden and may assist with maintaining functional stability of the digestive system.

“Panacur-C is considered relevant for managing parasitic conditions that lead to persistent digestive upset and secondary nutritional concerns.”

Quick Fact: Relief for Gastrointestinal Irregularity Panacur-C may be part of symptomatic management for diarrhea and vomiting caused by susceptible parasitic infections, contributing to improved comfort during symptomatic periods.

Regulatory References

1. DailyMed listing for Panacur-C

Who can and cannot use Panacur-C?

The population eligibility for Panacur-C (fenbendazole) is strictly defined by regulatory documentation, such as the FDA label, focusing on the approved species, age, and health status.

Official Eligibility and Contraindications

Population-Specific Restrictions

Official regulatory documents establish clear age and physiological rules for use:

• Age-Related Eligibility: Panacur-C is approved for use in puppies 6 weeks of age and older. Use is restricted for animals younger than 6 weeks.
• Conditional Use: If a dog or puppy is sick, administration is restricted until a veterinarian is consulted for diagnosis.
• Reproductive Status: The product is explicitly defined as safe for use in pregnant bitches and is also permitted for lactating bitches, with no stated restrictions for these populations.

These rules create a clear framework defining the populations for whom use is permitted and those for whom use is formally prohibited.

Interactions with other medicines and products

Interaction Profile Overview

The official regulatory profile for Panacur-C (Fenbendazole) is characterized by a general absence of known systemic drug-drug interactions. The official prescribing information explicitly states that there are no known contraindications or formal warnings based on co-administration risk with other medicinal products. Clinical data shows that the product was co-administered alongside a wide variety of substances, including antibiotics, steroids, anesthetics, tranquilizers, as well as common supplements like vitamins and minerals, with no incompatibilities revealed. This indicates a lack of officially documented pharmacokinetic (exposure-altering) or pharmacodynamic effects requiring clinical intervention.

Administration-Related Constraints

Although systemic interactions are not documented, regulatory documents contain specific procedural constraints related to its use. The product is subject to a drug-food administration restriction that mandates the granules must be thoroughly mixed with a small amount of the animal's usual food. This is a functional requirement to ensure the correct and complete oral administration of the medicine. Furthermore, official product summaries establish a physical mixing incompatibility rule. This restriction means that, in the absence of documented compatibility studies, the product must not be physically combined or mixed with other liquid or powdered veterinary medicinal products.

Official Interaction Classification

The overall interaction structure is defined by procedural and physical use constraints, rather than high-severity drug-drug interactions. The profile contains no formal statements defining metabolic interactions, transporter effects, or specific medicinal products that alter the drug's systemic exposure.

Panacur-C, containing fenbendazole, functions as a benzimidazole carbamate anthelmintic by exhibiting selective affinity for the beta-tubulin subunit within the targeted organism's intestinal and tegumental cells. This interaction is a binding-type inhibition that interferes with the molecular process of tubulin polymerization, the necessary step for the de novo formation of microtubules. The resulting microtubule destabilization and depolymerization disrupt intracellular transport mechanisms, specifically inhibiting the translocation of secretory vesicles, including those responsible for glucose uptake. The downstream cascade involves impaired nutrient absorption, leading to the depletion of intracellular energy reserves such as glycogen. This systemic energy deficit compromises cellular integrity and motility, initiating a generalized physiological stasis and eventual cellular destruction across multiple life stages of the target organism.

How to Use Panacur-C

The usage of Panacur-C is governed by a strict, three-day oral administration protocol, designed to deliver the required dose of fenbendazole. The product is supplied as 22.2% granules in pre-measured packets, and its use is strictly confined to the oral route.

Official Dosing and Frequency

The established daily dose for the treatment course is a fixed amount of 50 mg/kg (22.7 mg/lb) of body weight. This specific dose must be administered once daily for three consecutive days to constitute a complete treatment cycle. Due to the fixed dose rate, the animal must be accurately weighed before the start of treatment to ensure the correct packet size or combination is used.

Administration and Contextual Rules

The granules are intended to be mixed completely with a small portion of the animal’s usual food; it is required that the entire medicated amount of food be consumed to ensure full dosing. For dry food, it is specified that the food may need to be moistened to facilitate proper mixing and ingestion.

Panacur-C is officially approved for use in puppies six weeks of age or older and may be used in pregnant bitches. Procedural constraints specify that the medication must not be administered to a dog or puppy that is acutely sick. For animals whose weight falls between the standard packet sizes, the protocol directs the use of the next higher packet size to achieve the required 50 mg/kg dosage.

Panacur-C: Recent Clinical Evidence

Evidence for use in Gastrointestinal Parasite Management

Research supporting the regulatory review of Panacur-C was studied for evaluating research for specific parasitic helminths, including roundworms, hookworms, whipworms, and the Taenia genus of tapeworms. These investigations were structured around two main types of regulatory studies: controlled Pivotal Dose Confirmation Studies conducted in laboratory settings and Multi-site Field Effectiveness Studies involving animals under real-world conditions.

The main outcomes measured in these evaluations included quantitative measures of worm burden in controlled settings and changes in parasite fecal egg output (FECRT) in field studies. The assembled evidence base was determined to meet the criteria necessary for regulatory review by the U.S. Food and Drug Administration's Center for Veterinary Medicine (FDA-CVM). The findings describe patterns observed in the studies. The available research is confined to the specific parasitic species listed on the product labeling.

Evidence in Specific Populations and Age Groups

The core regulatory research examined use in the general canine population, including adult dogs and puppies (specifically those over 6 weeks of age). Research also explored the product’s use in pregnant female dogs, with these findings being part of the overall evidence assessment for the intended species.

The studies report outcomes observed in the populations during the short intervals examined post-treatment. While the research covered a variety of ages, results apply only to the populations studied and provide limited context regarding outcomes in very young or geriatric animals presenting with complex existing health issues.

Duration of Follow-up and Long-Term Data

Studies explored short-term symptom changes and status of parasite outcomes following the short, consecutive daily treatment regimen. The follow-up durations were limited, focusing on a narrow post-treatment window necessary to assess the measured study outcomes following administration. Research monitored the immediate physiological response and patterns related to measured outcomes.

There is limited information for long-term outcomes or the durability of the observed study patterns beyond the period required for immediate post-treatment evaluation. Consequently, long-term effects are not fully established, as the core regulatory research does not determine extended outcomes, maintenance patterns, or information related to future follow-up assessments.

Uncertainties and Areas Not Fully Studied

The research examined a defined set of gastrointestinal helminth infections. The data show patterns related to the primary outcomes monitored against the Taenia genus of tapeworms, but evidence is limited regarding the product’s action against other types of common tapeworms.

Furthermore, the evidence base provides limited insight into outcomes for severely ill animals, as these cases are often excluded from core clinical studies. Evidence is also limited regarding evaluating outcomes for other parasitic conditions that are not included in the labeled indications, such as Giardia. Study results reflect the specific conditions under which they were conducted, and comparative evidence between this product and all other commercially available dewormers is not part of the core regulatory review.

Key Studies & References

1. Freedom of Information Summary: Supplemental New Animal Drug Application (NADA) 121-473 for Panacur-C (Fenbendazole) Granules 22.2%
2. DailyMed: Panacur (fenbendazole) Granules 22.2% Product Information

Common questions about Panacur-C (FAQ)

Q: Is Panacur-C the same as the medication Fenbendazole?

A: Panacur-C is a registered brand name product containing the active ingredient Fenbendazole. According to official product descriptions, Panacur-C is a specific, regulated formulation of the Fenbendazole compound.

Q: How quickly do the effects of Panacur-C typically begin?

A: Regulatory documents indicate the product is administered over three consecutive days. The core studies focused on outcomes measured after the full treatment course, and specific, immediate onset timeframes are not detailed in the official product information.

Q: Can Panacur-C be used in smaller populations, like young children or elderly individuals?

A: The official product labeling strictly indicates that Panacur-C is NOT FOR USE IN HUMANS. It also carries a dedicated warning to keep the medication out of the reach of children. The product is only approved for use in dogs and puppies six weeks of age or older, and there are no approved human populations for this drug product.

Q: Can Panacur-C interact with common vitamins or supplements?

A: The official regulatory profile indicates a general absence of known systemic drug-drug interactions. Clinical data described in the product summary note that the medication was co-administered alongside substances like vitamins and minerals, and no incompatibilities were reported.

Q: What is the recommended period of time between using Panacur-C treatments?

A: The official instructions define the treatment as a specific three-day consecutive course. The product label does not provide an official interval or schedule for routine re-treatment or follow-up. Questions regarding repeated use are generally referred to a veterinarian as part of the label's guidance for the control of parasitism.

Q: Can Panacur-C be used for general preventative purposes?

A: The official indications describe its use for the treatment and control of specific diagnosed parasite infections. It is not officially labeled for a purpose described as general prevention.

Q: Is it normal to see changes in stool after starting Panacur-C?

A: Changes in stool consistency are noted in the safety data, with 'loose stools' listed as a reported event. Stool changes may also be part of the body's physiological response during the elimination of the targeted organisms.

Q: Why is Panacur-C sometimes mentioned in discussions outside its main official use?

A: Official post-market surveillance reports documented rare serious adverse events primarily associated with the use of the product that exceeded the official three-day labeled duration. This indicates that the product has been used in ways not consistent with the official directions for use.

Q: Does Panacur-C have an official safety classification?

A: According to the FDA, Panacur-C is classified as an Over-the-Counter (OTC) Animal Drug. Furthermore, the official product information confirms that it is not listed under the U.S. Controlled Substances Act (CSA) or similar regulatory schedules.

Q: Is the active substance in Panacur-C used for human treatments in other formulations?

A: While the specific Panacur-C product is prohibited for human use, its active ingredient, Fenbendazole, belongs to the benzimidazole class of anthelmintics. Other drugs within this same class, such as Mebendazole and Albendazole, are approved and utilized in human medicine.

Q: Can Panacur-C be used alongside an antibiotic, according to official documents?

A: Yes, the official profile confirms that the product was studied alongside a variety of other substances, including antibiotics. The clinical data revealed no incompatibilities or known systemic interactions when co-administered.

Q: What is the typical difference between the 'C' formulation and other Panacur versions?

A: The letter 'C' in Panacur-C is a designation indicating that this specific formulation is approved and labeled as a Canine Dewormer for use in dogs. Other Panacur versions are typically formulated, packaged, or approved for use in other animal species.

Q: What should be done if an official warning sign, like an allergic reaction, is observed with Panacur-C?

A: The official label specifies that a veterinarian should be consulted for diagnosis of illness before administration. For reporting a suspected adverse reaction, the label provides a dedicated contact number for the manufacturer.

Q: Does the efficacy of Panacur-C depend on what kind of food it is taken with?

A: Official instructions require that the granules be mixed with a small portion of the animal’s usual food. The label emphasizes the requirement to consume the entire medicated amount of food, but it does not specify that the type of food (e.g., wet vs. dry or composition) impacts the drug's action.

Q: What happens to the parasites that Panacur-C targets?

A: The product's mechanism is described as disrupting the parasite's cellular structure and preventing nutrient absorption. This action leads to the parasite’s eventual destruction and removal from the host system.

Q: Is Panacur-C known to cause temporary skin reactions or itching?

A: The list of officially documented adverse reactions from clinical studies focuses on gastrointestinal disorders, such as vomiting, loose stools, and lack of appetite. Skin reactions or itching are not listed as officially documented common side effects in the product's core safety profile.

Q: Does research indicate a link between Panacur-C use and changes in mental clarity?

A: The official product safety information summarizes adverse events reported in clinical studies. Changes in mental clarity or other central nervous system-related effects are not included in the list of officially documented side effects.

Q: What does the term 'broad-spectrum' mean in the context of Panacur-C?

A: The designation broad-spectrum anthelmintic describes the drug's purpose. It indicates that the product's action is effective against a variety of different types of parasitic worms (helminths), including roundworms, hookworms, and whipworms.

Q: Does Panacur-C have a specific classification under Controlled Substances Acts?

A: No, the product information states that Panacur-C is classified as an OTC animal drug and is not listed as a controlled substance under the U.S. Controlled Substances Act.

Storage and Disposal of Panacur-C (Fenbendazole Granule)

Panacur-C must be stored according to the requirements for stability and safety documented in official labeling.

Mandatory Storage Conditions

Disposal Instructions

Unused or expired fenbendazole must be disposed of in a manner that prevents release to the environment, as the active ingredient is classified with environmental toxicity warnings. Disposal should follow established guidelines for unused medicine, such as utilizing a drug take-back program or following proper household trash procedures. The product must not be discarded in a way that contaminates wastewater.